For example, paediatric ALL patients appear to suffer from cytokine-release syndrome and neurological toxicities more frequently than adult ALL patients following treatment with CD19-targeted CAR T-cell therapy.158. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.